Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer

Frontiers in Medicine, Год журнала: 2025, Номер 12

Опубликована: Март 11, 2025

Breast cancer (BC) is the most common malignant tumor in women and leading cause of cancer-related deaths women. As one subtypes breast cancer, patients with hormone receptor-positive (HR+) usually experience disease progression over an extended period time, triggering search for therapeutic strategies other than endocrine therapy. In recent years, continuous research on various targets has led to dramatic changes treatment patients, resulting prolonged clinical survival. With redefinition human epidermal growth factor-2 (HER2) expression, more precise individualized possible. This review comprehensively reviews targeted therapies critical trials HR+ tracks latest advances. It also provides valuable insights into future direction therapies.

Язык: Английский

---

Signaling pathway dysregulation in breast cancer

Oncotarget, Год журнала: 2025, Номер 16(1), С. 168 - 201

Опубликована: Март 13, 2025

// Dinara Ryspayeva 1 , 2 3 4 Attila A. Seyhan 5 William J. MacDonald Connor Purcell Tyler Roady Maryam Ghandali Nataliia Verovkina Wafik S. El-Deiry 7 Martin Taylor 6 and Stephanie L. Graff Laboratory of Translational Oncology Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA Department Pathology Medicine, Joint Program in Biology, Lifespan Health System Legorreta Center at Pathobiology Graduate Program, on the Biology Aging, Hematology/Oncology Division, Correspondence to: Ryspayeva, email: [email protected] Keywords: breast cancer; oncogenic pathways; signal dysregulation therapeutic approaches; clinical trials Received: December 20, 2024 Accepted: March 03, 2025 Published: 13, Copyright: © et al. This is an open access article distributed under terms Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, reproduction any medium, provided original author source are credited. ABSTRACT provides a comprehensive analysis signaling pathways implicated cancer (BC), most prevalent malignancy among women leading cause cancer-related mortality globally. Special emphasis placed structural dynamics protein complexes that integral to regulation these cascades. Dysregulation cellular fundamental aspect BC pathophysiology, with both upstream downstream cascade activation contributing process aberrations not only drive tumor growth, but also contribute resistance against current treatments. The review explores alterations within across different subtypes highlights potential strategies targeting pathways. Additionally, influence specific mutations decision-making examined, underscoring their relevance particular subtypes. discusses approved modalities ongoing disrupted However, further investigation necessary fully elucidate underlying mechanisms optimize personalized treatment approaches.

Язык: Английский

---

Buenos Aires Breast Cancer Symposium (BA-BCS 2024) A Second Successful “Trial” for Bringing Together both World Hemispheres To Debate the Future of Translational Breast Cancer Research

Journal of Mammary Gland Biology and Neoplasia, Год журнала: 2025, Номер 30(1)

Опубликована: Март 15, 2025

The second edition of the Buenos Aires Breast Cancer Symposium (BA-BCS), first held in person, took place from September 3rd to 6th Aires, Argentina. This report provides an overview talks delivered as individual lectures or part mini-symposia illustrating diversity and complexity topics discussed throughout meeting. event brought together leading scientists clinical experts dedicated advancing breast cancer research improving therapeutic strategies patient care. contributions both speakers attendees fostered extraordinary atmosphere at gathering Aires. We hope these interactions will lead more translational approaches promote future collaborations.

Язык: Английский

---

The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions

Medicina, Год журнала: 2025, Номер 61(3), С. 518 - 518

Опубликована: Март 17, 2025

Gene mutations in PIK3CA, the catalytic subunit of phosphoinositide 3-kinases, are significantly associated with prognosis breast cancer. This association suggests that cancer patients PIK3CA should receive mutant-specific treatment. review aimed to investigate novel treatments for PIK3CA-mutant study investigated effects respect gene ontology and PI3K/AKT/mTOR pathway. Subsequently, we comprehensively examined all clinical trials targeted mutations. Finally, this explored potential a new treatment noncoding RNA.

Язык: Английский

---

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3123 - 3123

Опубликована: Март 28, 2025

Multigene sequencing technologies provide a foundation for targeted therapy and precision oncology by identifying actionable alterations enabling the development of treatments that substantially improve clinical outcomes. This review emphasizes importance having molecular compass guiding treatment decision-making through multitude genetic mutations, showcasing why NGS plays pivotal role in modern oncology.

Язык: Английский

---